Precision IO’s Epione Robotic System Under Evaluation for Bone Lesion Treatment

Precision IO Group has initiated a new U.S. clinical study to assess the safety and performance of the Epione robotic platform for treating bone tumors and metastases. The trial aims to support the expansion of Epione’s U.S. market approvals.

The first patient was treated this past spring in a Miami cancer center. “Treating the first patient in the EPIOS clinical study shows a new opportunity for the treatment of bone lesions,” interventional radiologist Dr. Gina Landinez said.

The early-stage tumor-treating robotic platform Epione helps physicians perform percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. Developed by Quantum Surgical, a company specializing in robotics and artificial intelligence (AI), Epione allows physicians to treat inoperable tumors that are particularly difficult to reach due to their size or their location, at an early stage, simply and effectively, according to the company.

The new multi-center clinical study (EPIOS) will assess the Epione platform’s clinical performance in treating bone tumors and metastases to obtain an extension of its U.S. market approvals. The platform gained CE mark approval in September 2025.

“Percutaneous bone procedures are already a clinical reality in Europe, and we are committed to offer the same standard of care to our patients in the United States,” stated Dr. Sean Tutton, a professor at UC San Diego Health and the study’s lead investigator. “I’m thrilled to lead the EPIOS study, which is a major advancement in the expansion of robot-assisted guidance in the U.S., as bone procedures are one of the key indications for the Epione robotic platform.”

Although primary bone cancer is relatively rare, the development of bone metastases—often occurring several months or years after the initial cancer—is common, affecting one-third of cancer patients.¹

“This study represents a significant step forward for Precision IO Group and for the expansion of the robotic-assisted percutaneous ablation market,” Precision IO Group CEO Kurt Azarbarzin said. “I am proud to pursue it with three of our longstanding partners, whose teams fully understand the Epione technology and its potential to treat more patients.”

The Epione device is CE marked for abdomen, chest and musculoskeletal structure indications, and U.S. Food and Drug Administration-cleared for abdominal ablation indications. More than 1,500 patients have already been treated worldwide.

“In addition to the CE marking, we are really eager to validate the effectiveness of Epione in treating bone lesions in the U.S. Given that one-third of cancer patients suffer from bone metastases, many patients could benefit from our innovative technology,” commented Mohamed Shariff, vice president of Regulatory, Clinical and Market Access at Precision IO.

The parent company of Quantum Surgical, Precision IO Group Inc. is an interventional oncology company formed through the combination of Quantum Surgical and NeuWave Medical, two medical device firms. The Group brings together complementary technologies, deep clinical expertise, and global capabilities to advance cancer treatment. With a team of more than 250 employees worldwide, Precision IO Group develops innovations that empower physicians to deliver precise, minimally invasive treatments that improve patient outcomes. By integrating robotics, artificial intelligence, and remote-enabled interventions, Precision IO Group is attempting to redefine the standard of care in tumor ablation and shape the future of interventional oncology.

Reference
¹ InfoCancer